Glax­o­SmithK­line makes big down pay­ment on biotech tar­get­ing 'syn­thet­ic vi­a­bil­i­ty' with start­up fund­ing, pipeline deals

Since join­ing British drug­mak­er Glax­o­SmithK­line in 2018, CSO Hal Bar­ron has pushed to beef up the com­pa­ny’s on­col­o­gy port­fo­lio, tak­ing a par­tic­u­lar eye to “syn­thet­ic lethal­i­ty” dis­cov­ery work. Now, GSK is putting down a big chunk of change on the flip side of the coin — cell vi­a­bil­i­ty — for a range of po­ten­tial ther­a­pies out­side of can­cer.

GSK will co-lead a Se­ries A fi­nanc­ing round with an undis­closed amount of cash for Adres­tia Ther­a­peu­tics, a biotech hop­ing to de­vel­op med­i­cines tar­get­ing the “syn­thet­ic vi­a­bil­i­ty” of dys­func­tion­al or dy­ing cells in a range of ther­a­peu­tic ar­eas, GSK said Fri­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER